SCHEMBL2267918

SCHEMBL2267918

O=C(Nc1cc(-c2ccccc2)ccc1C(=O)O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.74
HDAC2 Q92769 3/20 0.67
DHODH Q02127 1/20 0.63
IGF2BP2 Q9Y6M1 1/20 0.58
SERPINE1 P05121 1/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
KMT2A Q03164 1/20 0.55
HDAC1 Q13547 2/20 0.55
PTGS1 P23219 1/20 0.53
HDAC3 O15379 1/20 0.53
MPO P05164 1/20 0.53
PPARG P37231 1/20 0.53
PPARD Q03181 1/20 0.53
PPARA Q07869 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
NTRK1 P04629 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272713 0.91 ACLY (0.84) ACLYHDAC2DHODHIGF2BP2HDAC1
SCHEMBL2274927 0.91 ACLY (0.63) ACLYHDAC2DHODHIGF2BP2SERPINE1
SCHEMBL2270222 0.90 DHODH (0.77) ACLYHDAC2DHODHIGF2BP2SERPINE1
SCHEMBL2272939 0.89 ACLY (0.71) ACLYHDAC2DHODHSERPINE1NPC1
SCHEMBL2276184 0.89 ACLY (0.73) ACLYHDAC2NPC1RAB9AKMT2A
SCHEMBL2275453 0.87 ACLY (0.76) ACLYHDAC2DHODHSERPINE1NPC1
SCHEMBL2274953 0.86 ACLY (0.67) ACLYHDAC2DHODHIGF2BP2SERPINE1
SCHEMBL2274023 0.86 ACLY (0.64) ACLYHDAC2DHODHKMT2AMPO
SCHEMBL21930987 0.86 ACLY (1.00) ACLYHDAC2SERPINE1
SCHEMBL2272605 0.85 DHODH (0.73) ACLYHDAC2DHODHIGF2BP2SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885HDAC2 276/4885DHODH 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.